Clinical Trials | A Randomized Phase II Study of CHO(E)P vs CC-486-CHO(E)P vs Duvelisib-CHO(E)P in Previously Untreated CD30 Negative Peripheral T-cell Lymphomas

The University of Virginia is conducting a clinical research study for adults ages 18 and over who have stage I-IV CD30 negative peripheral T-cell lymphoma that has not been previously treated. The purpose of the study is to see the effects of adding a study drug, duvelisib or CC-486 (azacytidine) to the usual combination of drugs. If you decide to take part in this study, you will either get the following treatments: • Your usual chemotherapy (CHOP or CHOEP) for up to 18 weeks • You will get the usual chemotherapy (CHOP or CHOEP) plus the study drug duvelisib for up to 18 weeks • You will get the usual chemotherapy (CHOP or CHOEP) plus the study drug CC-486 (azacitidine) for up to 18 weeks. The chemotherapy regimen known as CHOP includes the following drugs: cyclophosphamide (C), doxorubicin (H), vincristine (O), and prednisone (P). The chemotherapy regimen known as CHOEP includes the following drugs: cyclophosphamide (C), doxorubicin (H), vincristine (O), etoposide (E), and prednisone (P). If you are 60 years old or younger, you will receive CHOEP chemotherapy. After you finish your study treatment, your doctor will continue to follow your condition and watch you for side effects for up to 5 years after you finish study treatment. Study-related procedures that are being done beyond your standard of care will be provided at no cost to you or your insurance. Additional information can be found here: https://clinicaltrials.gov/study/NCT04803201 [email protected]